Oral Anabolic Steroids Cabergoline for Bodybuilding
Product Name: Cabergoline
Synonyms: 6-allyl-n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)ergoline-8-carboxamide;CABERGOLINE;(8-beta)-(2-propenyl);n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-ergoline-8-carboxamid;FCE-21336,Cabaser,Dostinex;(8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)- ergoline-8-carboxamide;Cabaser;Dostine
Chemical Properties White Crystalline Solid
Usage A dopamine D2-receptor agonist.
Usage receptor stimulant
2. adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas);
3. monotherapy of Parkinson's disease in the early phase;
4. combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson's disease;
5. in some countries also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis and galactorrhea);
6. treatment of uterine fibroids.
7. adjunctive therapy of acromegaly, cabergoline has low efficacy in suppressing levels and is highly efficient in suppressing hyperprolactinemia that is present in 20-30% of acromegaly cases;
8.and prolactin are similar structurally and have similar effects in many target tissues, therefore targeting prolactin may help symptoms when hormone secretion can not be sufficiently controlled by other methods;
9. Cushing's disease - cabergoline may be used to lower ACTH levels and cause regression of ACTH producing pituitary adenomas;
10. other pituitary adenomas - cabergoline has demonstrated certain efficacy in controlling or reducing other kinds of pituitary adenomas, as well as silent or non-functional adenomas.
Parkinson's disease: Monotherapy: Initial dose should be 0.5 mg daily. The usual maintenance dose is 2 to 4 mg daily. Combination therapy: Usually 2 to 6 mg daily.
Tumors of the pituitary gland and other hyperprolactinemic conditions: Initially 0.5 mg per week, slowly titrated to 4.5 mg per week, if necessary.
Ablactation: According to specific treatment scheme.
White or almost white crystarlline powder
1. IR complies
No more than 0.5%
1.Allylamide (USP,rel,D) no more than 0.10%
1.Dichloromethane no more than 100ppm;
Residue on ignition
NO more than0.10 %
NO more than 20ppm
90%af particles no mone than 80關m
Conforn with EP6.0/ USP38